Yulia Slavina

Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy

Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy
Allogene Therapeutics unveils ALLO-329

Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR T cell therapy designed for autoimmune disease treatment. The therapy leverages proprietary Dagger technology, aiming to reduce or eliminate the need for lymphodepletion in patients undergoing cell therapy.

This approach could represent a significant advancement in the management of autoimmune conditions by potentially minimizing side effects associated with standard lymphodepletion regimens. ALLO-329 remains under investigation and is not yet approved for commercial use. Further details about the clinical progress and potential impact of ALLO-329 can be found on Allogene Therapeutics' official site.

Allogene Therapeutics recently set its Q1 2026 earnings call for May 13 to provide updates on CAR-T and cell therapy development, according to a company announcement. The company’s CTO Ben Beneski is scheduled to join an industry panel on advancing next-generation cell-based therapies at a leading event, as reported in a previous update. These events reflect ongoing efforts by Allogene to advance its cell therapy pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.